The FDA has approved an immunotherapy combination therapy for adult patients with Bacillus Calmette-Guérin-naive, high-risk ...

Disease-free survival improved with durvalumab plus BCG induction/maintenance versus BCG alone, reducing recurrence/progression/death risk (HR 0.68; p=0.0154) with median DFS not reached. Eligibility ...

The FDA has approved durvalumab (Imfinzi, AstraZeneca) in combination with Bacillus Calmette-Guerin (BCG) for adults with BCG-naive, high-risk non-muscle-invasive bladder cancer (NIMBC). Approval was ...

Roswell Park urology experts shared studies at AUA 2026 on bladder and prostate cancer risk, pelvic floor neural mapping and ...

PROCEPT BioRobotics (Nasdaq: PRCT) today announced two milestones in its WATER IV prostate cancer clinical program: ...

Combination significantly improved disease-free survival in phase III trial ...

FDA approval establishes durvalumab plus BCG induction and maintenance as a new immunotherapy-based option for BCG-naïve, high-risk NMIBC following TURBT, potentially redefining the frontline ...

US FDA approves AstraZeneca’s Imfinzi for patients with BCG-naïve, high-risk non-muscle-invasive bladder cancer: Cambridge, UK Saturday, May 30, 2026, 13:00 Hrs [IST] AstraZene ...

Sequencing CAR T-cell therapy versus bispecific antibodies in myeloma increasingly hinges on MRD depth, transplant candidacy, ...

Two pre-TURBT 40-mg intravesical mitomycin-C instillations significantly improved long-term recurrence outcomes versus TURBT ...

Pelvic floor physical therapists share the best exercises to strengthen your pelvic floor. Here's how to do them.

Positive 12-Month Phase 2 data for NDV-01 demonstrated a 95% complete response (CR) rate at any time and a durable 76% CR rate at 12 months in ...